Skip to main content
SpringerLink
Log in

Acinetobacter baumannii infection in intensive care unit: analysis of distribution and drug resistance

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

The isolation rate and drug resistance rate of Acinetobacter baumannii (A.baumannii) have increased over the years, which has become one of the main causes of infection and death in intensive care unit (ICU) patients. Analysis of the distribution characteristics, drug resistance and influencing factors of A.baumannii in ICU could provide basis and reference for the infection prevention and clinical treatment.

Methods and Results

In this study, patients diagnosed with A.baumannii infection in ICU from January 2020 to December 2021 were selected. Samples of patients were collected for bacterial culture, drug sensitivity test analysis and drug resistant gene detection of A.baumannii. A total of 197 strains of A.baumannii were cultured in 2021, which was 18 strains more than in 2020. The specimens were mainly from lower respiratory tract secretions, and the isolated strains were multi-drug resistant. The resistance of isolates to tobramycin, gentamicin, and trimethoprim-sulfamethoxazole in 2021 showed a significant increase compared to 2020, while there were no significant differences observed in other resistance changes. The prevalence of multi-drug resistant A.baumannii in ICU remains high. Among them, all imipenem-resistant A.baumannii strains carried OXA-23 gene.

Conclusion

Clinical treatment should use antibiotics reasonably based on the characteristics of bacterial resistance, and strengthen the prevention and control of hospital infection, pay more attention to the disinfection and isolation to reduce the risk of cross infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Antunes LC, Visca P, Towner KJ (2014) Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis 71:292–301. https://doi.org/10.1111/2049-632X.12125

    Article  CAS  PubMed  Google Scholar 

  2. Sebeny PJ, Riddle MS, Petersen K (2008) Acinetobacter baumannii skin and soft-tissue Infection associated with War trauma. Clin Infect Dis 47:444–449. https://doi.org/10.1086/590568

    Article  PubMed  Google Scholar 

  3. Sahl JW, Johnson JK, Harris AD et al (2011) Genomic comparison of multi-drug resistant invasive and colonizing Acinetobacter baumannii isolated from diverse human body sites reveals genomic plasticity. BMC Genomics 12:291. https://doi.org/10.1186/1471-2164-12-291

    Article  PubMed  PubMed Central  Google Scholar 

  4. Thom KA, Hsiao WW, Harris AD, Stine OC, Rasko DA, Johnson JK (2010) Patients with Acinetobacter baumannii bloodstream Infections are colonized in the gastrointestinal tract with identical strains. Am J Infect Control 38:751–753. https://doi.org/10.1016/j.ajic.2010.03.005

    Article  PubMed  PubMed Central  Google Scholar 

  5. Howard A, O’Donoghue M, Feeney A, Sleator RD (2012) Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence; 3:243 – 50. https://doi.org/10.4161/viru.19700

  6. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B (2017) Clinical and pathophysiological overview of Acinetobacter Infections: a Century of challenges. Clin Microbiol Rev 30:409–447. https://doi.org/10.1128/CMR.00058-16

    Article  CAS  PubMed  Google Scholar 

  7. Martinez-Martinez L, Calvo J (2010) [The growing problem of antibiotic resistance in clinically relevant gram-negative bacteria: current situation]. Enferm Infecc Microbiol Clin; 28 Suppl 225–31. https://doi.org/10.1016/S0213-005X(10)70027-6

  8. Hsueh PR, Teng LJ, Chen CY et al (2002) Pandrug-resistant Acinetobacter baumannii causing nosocomial Infections in a university hospital, Taiwan. Emerg Infect Dis 8:827–832. https://doi.org/10.3201/eid0805.020014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nasr P (2020) Genetics, epidemiology, and clinical manifestations of multidrug-resistant Acinetobacter baumannii. J Hosp Infect 104:4–11. https://doi.org/10.1016/j.jhin.2019.09.021

    Article  CAS  PubMed  Google Scholar 

  10. Lin MF, Lan CY (2014) Antimicrobial resistance in Acinetobacter baumannii: from bench to bedside. World J Clin Cases 2:787–814. https://doi.org/10.12998/wjcc.v2.i12.787

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lee CR, Lee JH, Park M et al (2017) Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol 7:55. https://doi.org/10.3389/fcimb.2017.00055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fournier PE, Richet H (2006) The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42:692–699. https://doi.org/10.1086/500202

    Article  PubMed  Google Scholar 

  13. Playford EG, Craig JC, Iredell JR (2007) Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, Infection and their consequences. J Hosp Infect 65:204–211. https://doi.org/10.1016/j.jhin.2006.11.010

    Article  CAS  PubMed  Google Scholar 

  14. Weinstein MP, Clinical, Laboratory Standards I (2019) Performance standards for antimicrobial susceptibility testing, 30th edn. ed: Clinical and Laboratory Standards Institute

  15. Chang Y, Luan G, Xu Y et al (2015) Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front Microbiol 6:910. https://doi.org/10.3389/fmicb.2015.00910

    Article  PubMed  PubMed Central  Google Scholar 

  16. Doi Y, Murray GL, Peleg AY (2015) Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 36:85–98. https://doi.org/10.1055/s-0034-1398388

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mugnier PD, Poirel L, Naas T, Nordmann P (2010) Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 16:35–40. https://doi.org/10.3201/eid1601.090852

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Aboshakwa AM, Lalla U, Irusen EM, Koegelenberg CFN (2019) Acinetobacter baumannii Infection in a medical intensive care unit: the impact of strict Infection control. Afr J Thorac Crit Care Med 25. https://doi.org/10.7196/AJTCCM.2019.v25i1.239

  19. Garza-Gonzalez E, Camacho-Ortiz A, Ponce-de-Leon A et al (2023) Bacterial incidence and drug resistance from pathogens recovered from blood, cerebrospinal and pleural fluids in 2019–2020. Results of the Invifar network. PeerJ; 11:e14411. https://doi.org/10.7717/peerj.14411

  20. Wei Z, Zhou S, Zhang Y et al (2022) Microbiological characteristics and risk factors on prognosis associated with Acinetobacter baumannii bacteremia in general hospital: a single-center retrospective study. Front Microbiol 13:1051364. https://doi.org/10.3389/fmicb.2022.1051364

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lin MF, Lin YY, Lan CY (2019) A method to assess influence of different medical tubing on biofilm formation by Acinetobacter baumannii. J Microbiol Methods 160:84–86. https://doi.org/10.1016/j.mimet.2019.03.023

    Article  CAS  PubMed  Google Scholar 

  22. Urban C, Segal-Maurer S, Rahal JJ (2003) Considerations in control and treatment of nosocomial Infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 36:1268–1274. https://doi.org/10.1086/374847

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Thanks to our colleagues in the infection laboratory for their assistance.

Funding

This work was supported by Dazhou Science and Technology Bureau (21ZDYF0023) and Sichuan Medical Association (Q21062).

Author information

Authors and Affiliations

  1. Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, Sichuan province, China

    Siyang Zhao & Yanpeng Chu

  2. Department of Clinical Pharmacy, Dazhou Central Hospital, Dazhou, Sichuan province, China

    Bing Zhang, Conghai Liu & Xiaodong Sun

  3. College of Health Care Industry, Sichuan University of Arts and Science, No.56 nanyuemiao Street, Tongchuan District, Dazhou, Sichuan province, China

    Yanpeng Chu

Authors
  1. Siyang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Conghai Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaodong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanpeng Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.Z.: contributed to study design; B.Z.: contributed to study management and execution; C.L., X.S.: served as the medical advisors. All authors contributed to the final version of the manuscript.

Corresponding author

Correspondence to Yanpeng Chu.

Ethics declarations

Ethical approval

This study was conducted in accordance with the principles of the Declaration of Helsinki. This study was approved by the ethics committee of the hospital. As this is a retrospective study, the Ethics Committee is exempted from signing informed consent.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, S., Zhang, B., Liu, C. et al. Acinetobacter baumannii infection in intensive care unit: analysis of distribution and drug resistance. Mol Biol Rep 51, 120 (2024). https://doi.org/10.1007/s11033-023-09144-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11033-023-09144-3

Keywords

Search

Navigation